Lung Cancer Clinical Trials

Showing 761-780 of 3,692 trials

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

NCT04853017

This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides\]) as adjuvant treatment of minimal residual disease (MRD) in subjects with KRAS/neuroblastoma ras viral oncogene homolog (NRAS) mutated PDAC or other solid tumors.

Minimal Residual DiseaseKRAS G12DKRAS G12R+9 more

Elicio Therapeutics25 participantsStarted Oct 2021

Duarte, California, United States • Los Angeles, California, United States • Aurora, Colorado, United States +7 more locations

Active Not RecruitingPhase 1

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

NCT05492682

This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to obtain early information on the safety of this combination therapy.

Melanoma (Skin)Triple-Negative Breast CancerNon-Small Cell Lung Cancer+5 more

Valo Therapeutics Oy15 participantsStarted Feb 2023

Frankfurt, Germany • Heidelberg, Germany • Tübingen, Germany

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Related Searches

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

Safety and Efficacy of Lorbrena

Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer

Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer

A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy

Enhanced Assistance During Radiotherapy for Unmet Essential Needs

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

Centralized Lung Cancer EARly Detection Among Smokers (CLEAR Study)

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

Understanding Rural Patient and Provide Preferences for Mobile Lung Cancer Screening Clinics